The Friday Five: Your Weekly Market Briefing

Setup Snapshot

The Setup in One Card

How NTRA scored, how it moved against the market, and the catalyst behind the move. A high score means the stock deserves research time, not that it is a buy.

Friday Five Score

September 2026 Return

NTRA+28.37%

September 2026

+28.37% · Rank 1

Sector Trend

Leadingup 5.4 percent

Actionability

Extended

Catalyst

Clinical Data

The largest molecular residual disease dataset ever presented in lung cancer showed strong prognostic value for the Signatera test.

Top five stocks covered by The Friday Five in September, ranked by full month price return (August 31 close to September 30 close).

Continue the Research

Put NTRA Back in Context

The stock page is one piece of the weekly research. Continue with the original issue, the full public ranking, or the method behind the analysis.

Search Every Published Pick

Filter the full record by sector, issue or whether the pick beat the index.

Learn: Duration

Open the public plain-English explanation connected to this research.

Other Health Care names on this week's board

UNH · UnitedHealth Group Incorporated, view score card REGN · Regeneron Pharmaceuticals, Inc., view score card

← Back to the full scoreboard

This page is for educational and informational purposes only. It is not financial advice, investment advice, or a recommendation to buy or sell any security.

Natera, Inc. NTRA

The Setup in One Card

Put NTRA Back in Context